Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Dabrafenib in Hepatic Impairment
NCT02873650Phase 1Terminated
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dabrafenib + trametinib in melanoma (3 arms), sponsored by Novartis. Primary endpoints: Maximum plasma concentration at 96 hours, Area under the curve to the last measurable concentration at 96 hours and 6 more. Started Dec 2016; status: terminated.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02873650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873650.